Strategies For Ensuring Biomanufacturing Resilience For Biologics And Vaccines

In this article, we highlight key strategies for ensuring the reliable delivery of health technologies such as vaccines, drawn from the experience of MilliporeSigma during the global pandemic response and looking forward to how governments and the private sector can most effectively work together to deliver healthcare post-pandemic. These strategies focus on vaccines, monoclonal antibodies, and new modalities manufactured by biotechnology companies and institutes.